Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

308.08 +7.89 (+2.63%)
Official Closing Price Updated: 7:00 PM EDT, Aug 12, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Eli Lilly's JAK Inhibitor Baricitinib Cuts Death Risk By 13% In COVID-19 Patients
According to a British study, Eli Lilly And Co (NYSE: LLY) and Incyte Corporation's (NASDAQ: INCY) Olumiant (baricitinib) reduced the risk of death in... 
Via Benzinga
36 Stocks To Watch After Biden's First State of The Union Address
President Joe Biden hosted his first State of the Union Address Tuesday in front of members of Congress. In the speech, Biden discussed several items that he has already helped... 
Via Benzinga
Eli Lilly And 3 Other Stocks Sold By Insiders
Although US crude oil futures traded higher this morning, there were a few notable insider trades. When insiders sell shares, it indicates their concern in the company’s... 
Via Benzinga
Does the FDA Rollback Of Regeneron And Eli Lilly COVID Treatment EUAs Signal A Need To Look Beyond Monoclonal Antibodies? NanoViricides, Inc. Looks To Meet This Need With A New Approach
Photo credit: Marcelo Leal and Kate Hliznitsova on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended... 
Via Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first two sessions of the... 
Via Talk Markets
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first... 
Via Benzinga
Eli Lilly Stock Shows Improved Relative Strength Performance With 84 RS Rating
Eli Lilly reached a key technical benchmark, with its Relative Strength Rating moving into the 80-plus percentile with an upgrade to 84. 
Via Investor's Business Daily
FDA Approves Eli Lilly's Jardiance In Broader Heart Patient Population
The FDA approved Eli Lilly And Co (NYSE: LLY) and partner Boehringer Ingelheim's drug, Jardiance, for expanded use in reducing the risk of death and... 
Via Benzinga
The Daily Biotech Pulse: Lilly's Jardiance Gets Nod For Heart Failure, Pulmatrix Announces Reverse Split, Reata Awaits FDA Decision
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Lilly's Co-developed Diabetes Drug Jardiance Gets Label Expansion To... 
Via Benzinga
Eli Lilly Bets On RNA Potential With $700M Investment In Boston's Seaport
Eli Lilly And Co (NYSE: LLY) will dole out $700 million for a new research site at Boston's Seaport district as part of the Company's broader push into RNA... 
Via Benzinga
Nearly 66% Of Patients Respond To Eli Lilly's Mirikizumab In Ulcerative Colitis Study
Patients with moderately-to-severely active ulcerative colitis (UC) who took Eli Lilly And Co's (NYSE: LLY) mirikizumab achieved statistically superior clinical... 
Via Benzinga
Friday the 13th on the 18th
Today stock markets more or less panicked over the fear of war. 
Via Talk Markets
Beware Of Neutrals
Retail sales are up 3.9% while online sales are down for Jan. 
Via Talk Markets
ICER's Report Suggests Benefits Of Eli Lilly's Tirzepatide Not Better Than Other Diabetes Drugs
Institute for Clinical and Economic Review (ICER) casts doubts on Eli Lilly And Co’s (NYSE: LLY) tirzepatide, a type II diabetes candidate, about its usefulness to... 
Via Benzinga
Give peace a chance
Israeli fabless semiconductor maker Tower was bought by Intel for $5.4 bn today. 
Via Talk Markets
Lilly Unites With ImmunoGen In ADC Deal Worth Up To $1.7B
ImmunoGen Inc (NASDAQ: IMGN) has struck a multi-target license deal with Eli Lilly And Co (NYSE: LLY) to grant exclusive rights to research, develop, and... 
Via Benzinga
Market Briefing For Tuesday, Feb. 15
It's no secret that when inflation reaches the levels it is at now, the way out of it is to crush demand. This is the price for the Fed being 'behind the curve' all last year. 
Via Talk Markets
World Markets News For Monday
European markets were down over fear of Ukrainian battles. 
Via Talk Markets
AstraZeneca Stock Ranked No. 1 In Group; Recently Reported Record Sales, Strong Outlook
AstraZeneca reported record sales, and a bullish outlook. AstraZeneca stock is idling though amid market weakness. Setting up for run higher? 
Via Investor's Business Daily
Large Cap Biopharma- Well Positioned For Choppy Markets
If the past week is any indicator large-cap biopharma stocks are a good place to hide from the turbulence of 2022 markets. 
Via Talk Markets
A Lot To Like At Lilly
Eli Lilly, one of our highest-P/E portfolio holdings, is an exemplar of a richly valued growth stock that should easily sail inflationary waters. 
Via Talk Markets
JAK Inhibitors Come Under EMA Scrutiny On Safety Concerns: All You Need To Know
Following the FDA's issuance of a safety warning regarding JAK inhibitors, the safety committee of the European Medicines Agency initiated a review of these treatments,... 
Via Benzinga
Lilly's Antibody Receives FDA Emergency Use Nod For Mild-To-Moderate COVID-19
The FDA on Friday authorized Eli Lilly And Co's (NYSE: LLY) COVID-19 antibody drug for people aged 12 and older at risk of severe illness. The FDA authorized... 
Via Benzinga
Week In Review: US FDA Rejects Innovent/Lilly PD-1 NDA Based On China-Only Trial Subjects
A US FDA oncology advisory panel rejected the NDA submitted by Innovent and Lilly for their partnered anti-PD-1 antibody. Lilly tried to influence the panel by announcing it would offer the drug at a... 
Via Talk Markets
FDA AdComm Votes Against Lilly's Lung Cancer Drug, Sintilimab
The FDA advisory committee voted against the full approval of Eli Lilly And Co's (NYSE: LLY) lung cancer treatment over concerns that the clinical trial was... 
Via Benzinga
Psoriasis and the winter months: How one patient found relief to enjoy the holiday season
(BPT) - Sponsored by Eli Lilly and Company 
Via Brandpoint
The Daily Biotech Pulse: Adcom Recommends Additional Trials For Lilly's Partnered Cancer Drug, Novavax Touts Pediatric Vaccine Data, TC Biopharm IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adcom Rules That Lilly May Have To Conduct Additional Studies For Co-... 
Via Benzinga
Can Anyone Challenge Pfizer's Covid Dominance? Why These Biotechs Say Yes
Drug behemoth Pfizer was the first to launch a Covid antiviral pill — but a pack of small biotech stocks are already nipping at its heels. 
Via Investor's Business Daily
Preprint Suggests, Vir-GSK's COVID-19 Antibody Can Evade Omicron Sub-Variant
In January, amid the omicron surge, WHO's expert panel recommended GlaxoSmithKline Plc (NYSE 
Via Benzinga
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.